戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er pretreatment with a sequential regimen of cyproterone acetate (50 mg/kg/day for 21 days) and testo
2                                              Cyproterone acetate (CPA) is a steroidal antiandrogen us
3 xposure to hormonal treatments, particularly cyproterone acetate (CPA), has been posited to contribut
4 tetrachloride (CT), thioacetamide (THA), and cyproterone acetate (CPA).
5                  FHT (E2 valerate 2 mg/d and cyproterone acetate 25 mg/d) was prescribed at baseline
6 This event was blocked by the anti-androgens cyproterone acetate and hydroxyflutamide.
7 sm and the pharmacokinetics of two ADT drugs Cyproterone acetate and Leuprolide acetate for individua
8                 Increasing concentrations of cyproterone acetate and mifepristone resulted in more co
9                         Molecular docking of cyproterone acetate and RU486 into the homology model fo
10 tar-Unilever rats by a sequential regimen of cyproterone acetate and testosterone propionate, followe
11 n and transdermal estradiol with mostly oral cyproterone acetate as antiandrogens in transgender wome
12                               The antagonist cyproterone acetate behaved as a full antagonist of D11F
13 hibited by the addition of the anti-androgen Cyproterone Acetate demonstrating that the effects of FG
14  cells, RU486 revealed a higher potency than cyproterone acetate to prevent responses to dexamethason
15     The agonist activity of the antiandrogen cyproterone acetate was abolished in ebp1 transfectants.
16                         The steroid compound cyproterone acetate was identified in a high-throughput
17 ties of weak androgens and an AR antagonist (cyproterone acetate) are still dependent on the AR NH(2)
18                             AR activation by cyproterone acetate, a partial agonist that did not supp
19 s seen only with R1881, dihydrotestosterone, cyproterone acetate, and hydroxyflutamide.
20 s, hydroxyflutamide, bicalutamide (casodex), cyproterone acetate, and RU58841, and other compounds su
21 ol and medroxyprogesterone) and antagonists (cyproterone acetate, hydroxyflutamide and bicalutamide).
22 ynthetic potent progestigens, norethynodrel, cyproterone acetate, norethindrone, and megestrol acetat
23 ta-catenin to the AR DBD in vitro and to the cyproterone acetate-liganded AR in vivo.
24 th DHT in combination with the anti-androgen cyproterone acetate.
25 orticoid spironolactone and the antiandrogen cyproterone acetate.
26  standardized GAHT, comprising estrogens and cyproterone acetate.
27                    The binding affinities of cyproterone and RU486 for the GR and progesterone recept
28               However, in contrast to RU486, cyproterone lacks a bulky side chain at position C11 bet
29                                              Cyproterone may therefore inhibit transactivation of the
30                                              Cyproterone (Schering AG) is clinically used as an antia
31            Despite its progestin properties, cyproterone shares a similar pharmacological profile wit